Variation in the use of pulmonary vasodilators in children and adolescents with pulmonary hypertension: a study using data from the MarketScan® insurance claims database

O’Byrne, Michael L.; Faerber, Jennifer; Katcoff, Hannah; Frank, David B.; Davidson, Alex; Giglia, Therese M.; Avitabile, Catherine M.

doi:10.1177/2045894020933083

Cited by 4 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MarketScan database is one of the largest sources of longitudinal, de‐identified healthcare reimbursement data for children ages 0 to 18 years. 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 The data are aggregated from US commercial and public payers, including inpatient, outpatient, emergency department, and pharmacy encounters, and constitute a convenience sample which is geographically representative. Data were directly extracted from the MarketScan database and included presence of cardiac disease as well as sex, race, ethnicity, census region, and insurance type.…”

Section: Methodsmentioning

confidence: 99%

Adherence With Lipid Screening Guidelines in Children With Acquired and Congenital Heart Disease: An Observational Study Using Data From The MarketScan Commercial and Medicaid Databases

Berger

Faerber

Chen

et al. 2022

JAHA

Self Cite

View full text Add to dashboard Cite

Background Universal lipid screening in children provides an opportunity to mitigate the lifetime risk of atherosclerosis, particularly in children with chronic conditions that are predisposed to early atherosclerosis. In response, national guidelines recommend additional early screening in a subset of cardiac conditions. The penetration of such guidelines has not been evaluated. Methods and Results We performed a retrospective study of a geographically representative sample of US children using the MarketScan Commercial and Medicaid claims databases. The study population was children with cardiac disease between ages 2 and 18 years and ≥3 years of continuous coverage from January 1, 2013, to June 30, 2018, divided into 4 major strata of heart disease. We assessed the likelihood of screening between these classifications and compared with healthy children and calculated multivariate models to identify patient factors associated with screening likelihood. Of the eligible 8.4 million children, 155 000 children had heart disease, of which 1.8% (31 216) had high‐risk conditions. Only 17.5% of healthy children underwent lipid screening. High‐risk children were more likely to be screened (odds ratio [OR], 2.1; 95% CI, 2.09–2.19; P <0.001) than standard‐risk children, but that likelihood varied depending on strata of cardiac disease (22%–77%). Timing of screening also varied, with most occurring between ages 9 and 11 years. Among cardiac conditions, heart transplantation (OR, 16.8; 95% CI, 14.4–19.7) and cardiomyopathy (OR, 2.9; 95% CI, 2.8–3.1) were associated with the highest likelihood of screening. Conclusions Children with cardiac disease are more likely to undergo recommended lipid screening than healthy children, but at lower rates and later ages than recommended, highlighting the importance of quality improvement and advocacy for this vulnerable population.

show abstract

Section: Methodsmentioning

confidence: 99%

Adherence With Lipid Screening Guidelines in Children With Acquired and Congenital Heart Disease: An Observational Study Using Data From The MarketScan Commercial and Medicaid Databases

Berger

Faerber

Chen

et al. 2022

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…This expands the scope of addressable questions to include longitudinal follow‐up. There are a number of vendors for insurance claims data generating data sets of recipients of commercial insurance like Optum deidentified Clinformatics® DataMart (Optum Inc.), 40–42 public insurance (state Medicaid or Medicare), or data sets with recipients of both commercial and public insurances (Marketscan [Truven Healthcare IBM Watson Health]) 43–51 . There are limitations to these data sets.…”

Section: Sources For Cost Datamentioning

confidence: 99%

“…There are a number of vendors for insurance claims data generating data sets of recipients of commercial insurance like Optum deidentified Clinformatics ® DataMart (Optum Inc.), [40][41][42] public insurance (state Medicaid or Medicare), or data sets with recipients of both commercial and public insurances (Marketscan [Truven Healthcare IBM Watson Health]). [43][44][45][46][47][48][49][50][51] There are limitations to these data sets. The identity of hospitals at which care is received are not available, which cannot only limit the options for calculating costs from claimed charges but also interferes with the ability to perform research into performance of or variation between hospitals.…”

Section: Measuring Costsmentioning

confidence: 99%

Incorporating economic analysis in interventional cardiology research

O’Byrne

Wilensky

Glatz

2022

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

Evaluative research in interventional cardiology has focused on clinical and technical outcomes. Inclusion of economic data can enhance evaluative research by quantifying the relative economic burden incurred by different therapies. When combined with clinical outcomes, cost data can provide a measure of value (e.g., marginal cost‐effectiveness). In some select situations, cost data can also be used as surrogates for complexity of care and morbidity. In this narrative review, we aim to provide a framework for the application of cost data in clinical trials and observational research, detailing how to incorporate this kind of data into interventional cardiology research.

show abstract

Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases

O’Byrne

Faerber

Katcoff

et al. 2022

American Heart Journal

View full text Add to dashboard Cite

Variation in the use of pulmonary vasodilators in children and adolescents with pulmonary hypertension: a study using data from the MarketScan® insurance claims database

Cited by 4 publications

References 40 publications

Adherence With Lipid Screening Guidelines in Children With Acquired and Congenital Heart Disease: An Observational Study Using Data From The MarketScan Commercial and Medicaid Databases

Adherence With Lipid Screening Guidelines in Children With Acquired and Congenital Heart Disease: An Observational Study Using Data From The MarketScan Commercial and Medicaid Databases

Incorporating economic analysis in interventional cardiology research

Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases

Contact Info

Product

Resources

About